Clinical Trial

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-22; most recent amendment 2026-05-15.
Status change: Not Yet Recruiting → Recruiting 2023-08-07
Trial Details
NCT Number NCT05884255
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Advanced Gastroenteropancreatic Neuroendocrine Tumor
Enrollment 220 participants
Start Date 2023-07-06
Primary Completion 2026-12 (estimated)
Study Completion 2030-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-19